Comscore Reports Q2 2024 Earnings Reflecting Strategic Transition
Comscore's Q2 2024 earnings show a decline in revenue but highlight a strategic shift towards growth by Q4 2024.
- Latest
- Trending
Comscore's Q2 2024 earnings show a decline in revenue but highlight a strategic shift towards growth by Q4 2024.
Supernus Pharmaceuticals sees a 24% YoY revenue increase in Q2 2024, driven by key drugs Qelbree and GOCOVRI.
Veracyte's Q2 revenue surged 27% to $114.4M, fueled by strong demand for genomic tests. Full-year guidance raised to $432M-$438M.
Postal Realty Trust's Q2 2024 highlights strong property acquisitions and lease renewals, pointing to steady future growth.
Stifel revises Celsius Holdings' price target to $61, citing future sales adjustments and increased spending. Buy rating maintained.
TG Therapeutics' Q2 2024 results show BRIUMVI sales at $72.6M, prompting a revenue guidance raise to $290-$300M.
Amgen's Q2 profit drops due to higher expenses, but revenue sees a 20% increase, driven by Horizon acquisition.
Ubisoft unveils 'Captain Laserhawk' on Ethereum Layer-2 Arbitrum—a community-driven, transmedia game inspired by Netflix’s "Blood Dragon Remix."
Thoma Bravo seeks $2 billion valuation for ESG software maker Cority, engages Goldman Sachs for potential sale process.
MoonTaurus (MNTR) predicted to surge 1400% by 2024, surpassing Shiba Inu and Dogecoin. Early presale frenzy drives massive investor interest.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.